Glycosylated peptide are used as a mediators of key biological function with unique intrinsic properties with potential to treat variety of diseases. Glycosylation of peptide drugs benefits with key features such as increased half-life, provides extended dosing duration, better solubility, and improved response to the therapy. The key factors that drive the market growth are the benefits of these peptides that show high biological activity, availability of innovative peptides in the market, and rise in incidence of chronic diseases worldwide. However, the intrinsic complexity for manufacturing and high cost of the active pharmaceutical ingredient (API) restricts the market growth. Nevertheless, ongoing R&D activities and increase in investment by the pharmaceutical companies offer ample opportunities to the market growth.
This global market is segmented on the basis of product type such as monoclonal antibodies (MABs), erythropoietin (EPO), and others. Based on application, the market is divided into oncology, blood disorder, and others. By geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The key players operating in the market include Sandoz International GmbH, Pfizer Inc. Roche Ltd, Teva Pharmaceuticals Industries Ltd, Celltrion Inc., Biocon Ltd., Dr.Reddys Laboratories Ltd, Medtronic plc, Cipla Inc, and Bachem Americas, Inc.
- The study provides an in-depth analysis of the global glycosylated peptide market along with current trends and future estimations to elucidate the imminent investment pockets.
- It presents a quantitative analysis from 2016 to 2023 to enable the stakeholders to capitalize on the prevailing market opportunities.
- Extensive analysis of the market by product assists to understand the various forms of autoimmune disease diagnostic available.
- Key players are profiled and their strategies are analyzed thoroughly to predict the competitive outlook of the market.
Glycosylated Peptide Market Key Segments:
By Product Type
- Monoclonal Antibodies (MABs)
- Erythropoietin (EPO)
- Blood Disorder
- North America
- Rest of Europe
- Rest of Asia-Pacific
- South Africa
- Rest of LAMEA